A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma

Model scores of the 29,894 trials active now.

Model score 23% for any early termination, 11% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2021-04-08. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: carcinomaulndlcellheart
  Phrases that lowered it: femalelinecombinationadvanced oropen label
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Drug's FAERS reports marked serious: 53.7% (lowers risk) · Drug's FDA history
• Sponsor's past termination rate: 6.5% (lowers risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Maximum age: 85 (lowers risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Drug's FAERS reports with a death: 21.6% (raises risk) · Drug's FDA history
• Trials the sponsor started in the prior 2 years: 13 (raises risk) · Sponsor's track record
• Drug's FAERS reports before start: 4776 (raises risk) · Drug's FDA history
• Has a data monitoring committee: No (lowers risk) · Design
• Blinding: none (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors NCT03945773 · started 2020 · scored riskier than 86% of active trials completed
• Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA) NCT03425201 · started 2019 · scored riskier than 51% of active trials completed
• Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma. NCT04066595 · started 2020 · scored riskier than 71% of active trials terminated
• A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment NCT04338269 · started 2020 · scored riskier than 16% of active trials terminated
• Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer NCT03542877 · started 2018 · scored riskier than 77% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.